Edition:
United States

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

7.08USD
12:38pm EDT
Change (% chg)

$0.45 (+6.79%)
Prev Close
$6.63
Open
$6.75
Day's High
$7.13
Day's Low
$6.75
Volume
25,742
Avg. Vol
14,085
52-wk High
$7.76
52-wk Low
$4.75

Latest Key Developments (Source: Significant Developments)

Mesoblast Updates On Phase 3 Trial For Acute Graft Versus Host Disease
Wednesday, 19 Sep 2018 11:29pm EDT 

Sept 20 (Reuters) - Mesoblast Ltd ::UPDATES ON PHASE 3 TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE.PHASE 3 TRIAL SUCCESSFULLY MET PRIMARY ENDPOINT OF DAY 28 OVERALL RESPONSE TO REMESTEMCEL-L TREATMENT.MULTI-INFUSION REGIMEN IN BOTH EAP AND PHASE 3 TRIAL WAS WELL TOLERATED.  Full Article

Mesoblast ‍Enters $75 Mln Non-Dilutive Credit Facility
Tuesday, 6 Mar 2018 06:31pm EST 

March 7 (Reuters) - Mesoblast Ltd ::ENTERED US$75 MILLION NON-DILUTIVE, FOUR-YEAR CREDIT FACILITY WITH HERCULES CAPITAL.‍PROCEEDS OF CREDIT FACILITY​ WILL BE PRIMARILY USED TOWARDS FUNDING COMMERCIALIZATION OF MSC-100-IV ​.  Full Article

Mesoblast Says ‍Primary Endpoint Achieved In A Phase 3 Cell Therapy Trial
Wednesday, 21 Feb 2018 04:48pm EST 

Feb 22 (Reuters) - Mesoblast Ltd ::‍PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN MESOBLAST'S PHASE 3 CELL THERAPY TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE​.  Full Article

Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA​
Wednesday, 20 Dec 2017 07:37pm EST 

Dec 21 (Reuters) - Mesoblast Ltd ::‍U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY ​.  Full Article

Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment
Wednesday, 20 Dec 2017 06:00am EST 

Dec 20 (Reuters) - Mesoblast Ltd ::MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT.MESOBLAST LTD - TOP-LINE RESULTS FROM PHASE 3 TRIAL ARE EXPECTED IN Q1 2018.  Full Article

Tigenix Announces Grant From Mesoblast Of Exclusive Global Patent License In Local Treatment Of Fistulae
Friday, 15 Dec 2017 02:32am EST 

Dec 15 (Reuters) - Tigenix Nv ::MESOBLAST GRANTS TIGENIX AN EXCLUSIVE GLOBAL PATENT LICENSE TO USE ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN THE LOCAL TREATMENT OF FISTULAE (EN).AGREEMENT INCLUDES RIGHT FOR CO TO GRANT SUB-LICENSES TO AFFILIATES AND THIRD PARTIES.MESOBLAST WILL RECEIVE SINGLE DIGIT ROYALTIES ON NET SALES OF CX601.MESOBLAST WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS.  Full Article

Mesoblast Says Granted Tigenix Access To Certain Of Its Patents
Thursday, 14 Dec 2017 06:20pm EST 

Dec 15 (Reuters) - Mesoblast Ltd ::CO WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS ​.‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​.  Full Article

Mesoblast says ‍qtrly loss attributable $7 mln
Tuesday, 14 Nov 2017 03:45pm EST 

Nov 15 (Reuters) - Mesoblast Ltd ::‍Qtrly loss attributable $7 million versus loss of $19.8 million.Qtrly revenue $1.2 million versus $395,000‍​.  Full Article

MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
Friday, 10 Nov 2017 09:49am EST 

Nov 10 (Reuters) - Mesoblast Ltd ::MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS.‍INFUSIONS WERE WELL-TOLERATED AND THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED DURING 52-WEEK PERIOD IN TRIAL​.  Full Article

Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment
Thursday, 28 Sep 2017 06:00am EDT 

Sept 28 (Reuters) - Mesoblast Ltd :Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment.  Full Article